share_log

Lyell Immunopharma Shares Are Trading Higher. The Stock May Be Moving on Continued Strength After the Company Announced Yesterday It Will Present Clinical Data From Its Phase 1-2 Trial of IMPT-314 CAR T-cell Therapy for B-cell Lymphoma at ASH 2024.

Benzinga ·  Nov 7, 2024 01:07
Lyell Immunopharma Shares Are Trading Higher. The Stock May Be Moving on Continued Strength After the Company Announced Yesterday It Will Present Clinical Data From Its Phase 1-2 Trial of IMPT-314 CAR T-cell Therapy for B-cell Lymphoma at ASH 2024.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment